Milatuzumab (or hLL1) is an anti-CD74[1] humanized monoclonal antibody for the treatment of multiple myeloma non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

[2][3] The drug is the first anti-CD74 antibody that has entered into human testing and is currently being studied for the treatment of multiple myeloma.

It is present in limited amounts in normal tissues but widely found in leukemias, lymphomas and the vast majority of multiple myeloma cases.

[citation needed] CD74 is involved in a cell-to-cell communication pathway that is critical for survival.

[citation needed] In preclinical studies with human lymphomas and myelomas, both naked Milatuzumab and the Milatuzumab conjugated with doxorubicin,[4] an antibody-drug conjugate or ADC, have demonstrated anti-lymphoma activity in-vivo.